Page last updated: 2024-10-30

leflunomide and Caplan Syndrome

leflunomide has been researched along with Caplan Syndrome in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Caplan Syndrome: A condition characterized by the presence of RHEUMATOID ARTHRITIS associated with a specific form of pneumoconiosis, often in coal miners and asbestos workers.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Yasmine, M1
Kaouther, M1
Dhia, K1
Hanene, F1
Wafa, T1
Dorra, BN1
Wafa, H1

Other Studies

1 other study available for leflunomide and Caplan Syndrome

ArticleYear
Treatment with Rituximab in Rheumatoid Pneumoconiosis: A Case Report.
    Current drug safety, 2023, Volume: 18, Issue:3

    Topics: Aged; Arthritis, Rheumatoid; Caplan Syndrome; Humans; Leflunomide; Male; Pneumoconiosis; Rituximab

2023